{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:07:42Z","timestamp":1789031262965,"version":"build-2803163510"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Acute inflammatory relapses in primary CNS demyelinating diseases, including relapsing multiple sclerosis (RMS), MOG-antibody-associated disease (MOGAD), and neuromyelitis optica spectrum disorder (NMOSD), drive hospitalization, disability, and socioeconomic burden. Blood-based biomarkers are increasingly used for relapse detection and treatment monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Investigate effects of corticosteroids on short-term dynamics of serum biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a pilot prospective study of 22 patients with acute neuro-inflammatory conditions, assessing changes in an 18 protein serum biomarker panel (Octave MSDA) and composite disease scores before and after high-dose intravenous methylprednisolone (IVMP; 1000 mg\/day for 3 days). Samples were collected within 24\u2005h before and after treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 14 RMS patients, IVMP produced significant decreases in GFAP, Serpin A9, FLRT2, contactin-2, protogenin, MOG, CXCL9, CD6, BAFF (TNFSF13B), IL-12B, and CDCP1. Composite MSDA scores showed paradoxical post-IVMP increases in overall disease activity, neuroinflammation, immunomodulation, and neuroaxonal integrity, with decreased myelin biology scores. In a pooled non-RMS group (MOGAD, NMOSD, idiopathic optic neuritis, and transverse myelitis), CNTN2 and IL-12B exhibited similar corticosteroid responsive reductions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings suggest that high-dose corticosteroids rapidly and significantly alter multiple serum biomarkers and composite activity scores across demyelinating conditions, underscoring implications for biomarker timing, interpretation, and future validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20552173261487037","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:54:36Z","timestamp":1788782076000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Acute effects of high-dose corticosteroids on serum biomarker profiles in primary CNS demyelinating disease: A pilot study"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-578X","authenticated-orcid":false,"given":"Anastasia P","family":"Chumakova","sequence":"first","affiliation":[{"name":"University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8547-5774","authenticated-orcid":false,"given":"Michael","family":"Demetriou","sequence":"additional","affiliation":[{"name":"University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4826-0066","authenticated-orcid":false,"given":"Michael","family":"Sy","sequence":"additional","affiliation":[{"name":"University of California, Irvine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101009"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109688"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2448"},{"key":"e_1_3_2_5_2","article-title":"Glucocorticoids target the CXCL9\/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury","volume":"8","author":"Riedel JH","unstructured":"Riedel JH, Robben L, Paust HJ, et al. Glucocorticoids target the CXCL9\/CXCL10-CXCR3 axis and confer protection against immune-mediated kidney injury. JCI Insight 2023 Jan 10; 8: e160251. PMID: 36355429; PMCID: PMC9870076.","journal-title":"JCI Insight"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03635-9"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1520112113"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2383"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52187"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.27096"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1998.0362"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.5.2231"},{"key":"e_1_3_2_13_2","first-page":"205521732513310","article-title":"Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis","volume":"11","author":"Sanchez A","unstructured":"Sanchez A, Sheng E, Eagleman S, et al. Real-world clinical utility of a multi-protein, blood-based biomarker assay for disease activity assessments in multiple sclerosis. Mult Scler J Exp Transl Clin 2025 Apr 16; 11: 20552173251331030. PMID: 40292039; PMCID: PMC12033869.","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-026-00984-2"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1177\/13524585261439680"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1538555"}],"container-title":["Multiple Sclerosis Journal \u2013 Experimental, Translational and Clinical"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261487037","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20552173261487037","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20552173261487037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T08:17:59Z","timestamp":1789028279000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20552173261487037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/20552173261487037"],"URL":"https:\/\/doi.org\/10.1177\/20552173261487037","relation":{},"ISSN":["2055-2173","2055-2173"],"issn-type":[{"value":"2055-2173","type":"print"},{"value":"2055-2173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"20552173261487037"}}